newsfilter
← Latest News
GlobeNewswire·

SAB BIO to Participate in Chardan 10th Annual Healthcare Conference

  • SAB Biotherapeutics management will participate in the Chardan 10th Annual Healthcare Conference on October 20, 2026, from 11:15 to 11:30 a.m. ET in New York, NY.
  • CEO Samuel J. Reich will present a fireside chat at the event, with a webcast available for registration.
  • One-on-one meetings with management are available for interested parties through their conference representatives.
  • SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human immunoglobulin G (hIgG) therapies for immune & autoimmune disorders using transchromosomic cattle technology.
  • The company's lead candidate, SAB-142, targets Type 1 diabetes (T1D) to delay onset & prevent progression in Stage 3 patients.
  • SAB-142 is currently being evaluated in a registrational Phase 2b clinical trial named SAFEGUARD for newly diagnosed Stage 3 autoimmune T1D patients.